Skip to content
Artwork for Dr. John Campbell
Dr. John Campbell · Today · 7 min

Most common symptoms and immunity

Runny nose, 76%. Headache, 75% Sneezing, 66% Sore throat, 52% Loss of smell, 52% Uploaded 07-10-21 https://covid.joinzoe.com/blog https://www.youtube.com/watch?v=xoGqyFUoUSw Most common symptoms in vaccinated and children Runny nose, 76% Headache, 75% Sneezing, 66% Sore throat, 52% Loss of smell, 52% (Fever nor chronic cough in the top symptoms) Out of date government advice misses 40% of infections Natural immunity, levels of protection against reinfection Natural infection alone in past year, 65% 2 doses of AZ in past 6 months, 71% 2 doses of Pfizer in past 6 months, 83% Infection (past year) followed by 2 doses of AZ, 90% Infection (past year) followed by 2 doses of Pfizer, 94% Contradicts Israeli data Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1.full.pdf Protection from prior SARS-CoV-2 infection, 94·8% Hospitalization 94·1% Severe illness 96·4% Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

0:00-7:48

transcript

No transcript — this publisher did not publish one.

show notes

Runny nose, 76%. Headache, 75% Sneezing, 66% Sore throat, 52% Loss of smell, 52%

Uploaded 07-10-21

https://covid.joinzoe.com/blog

https://www.youtube.com/watch?v=xoGqyFUoUSw

Most common symptoms in vaccinated and children

Runny nose, 76%

Headache, 75%

Sneezing, 66%

Sore throat, 52%

Loss of smell, 52%

(Fever nor chronic cough in the top symptoms)

Out of date government advice misses 40% of infections

Natural immunity, levels of protection against reinfection

Natural infection alone in past year, 65%

2 doses of AZ in past 6 months, 71%

2 doses of Pfizer in past 6 months, 83%

Infection (past year) followed by 2 doses of AZ, 90%

Infection (past year) followed by 2 doses of Pfizer, 94%

Contradicts Israeli data

Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel

https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1.full.pdf

Protection from prior SARS-CoV-2 infection, 94·8%

Hospitalization 94·1%

Severe illness 96·4%

Learn more about your ad choices. Visit megaphone.fm/adchoices

Learn more about your ad choices. Visit megaphone.fm/adchoices

links4

more episodes

All episodes